UNSPSC 51312705: Clemastine hydrogen fumarate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H26ClNO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19259EGQ3D, chemically known as pyrrolidine, 2-(2-(1-(4-chlorophenyl)-1-phenylethoxy)ethyl)-1-methyl-, (r-(r*,r*))-, (e)-2-butenedioate (1:1), but more generally known as clemastine hydrogen fumarate, which bears US NIH Compound Identifier 5281069.

European Medicines Agency schedules clemastine hydrogen fumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06648MIG. Most nations, for tariff purposes, schedule clemastine hydrogen fumarate under HS 29339990. SMILES: C[C@@](C1CCCCC1)(C2CCC(CC2)CL)OCC[C@H]3CCCN3C.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51312705 Clemastine hydrogen fumarate is a Commodity code that nominally names a specific antihistamine active pharmaceutical ingredient, but recent state and local opportunities tagged under it show little alignment with that narrow scope. The three most recent solicitations involve naloxone and drug deactivation systems procurement, a therapeutic pharmacy initiative inquiry covering direct-to-manufacturer prescription programs, and a multistate cooperative pharmaceutical and OTC products contract. State and local governments use this code — or tag opportunities under it — when procuring finished pharmaceutical products, including controlled substances and community health supplies, rather than raw chemical ingredients. Issuing bodies are diverse: a county health department (Seminole County, Florida), a state HHS commission (Texas), and a multistate cooperative purchasing alliance administered by a state department of administration (MMCAP, Minnesota). The mismatch between the code's chemical-compound title and the actual procurement activity suggests either systematic miscoding in state and local systems or use of a catch-all pharmaceutical code when more specific UNSPSC categories are unavailable.

Recent activity spans Florida, Texas, and the MMCAP membership (Minnesota with Oregon mentioned). Seminole County issued an IFB on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023 (note: the posted and due dates appear inconsistent in the source), with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract offers a two-year initial term with a one-year renewal option and will be awarded on a fixed-fee basis. The Texas Health and Human Services Commission posted a Request for Information (RFI) on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs before issuing a formal RFP; no budget or award value was disclosed. MMCAP, administered by Minnesota's Department of Administration, posted an RFP on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers, with awarded agreements effective July 1, 2026, and no specific budget disclosed.